- Home
- BYSI vs AVTX Comparison
BYSI vs AVTX Comparison
Compare BYSI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- AVTX
- Stock Information
- Founded
- BYSI 2010
- AVTX 2011
- Country
- BYSI United States
- AVTX United States
- Employees
- BYSI N/A
- AVTX N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- BYSI Health Care
- AVTX Health Care
- Exchange
- BYSI Nasdaq
- AVTX Nasdaq
- Market Cap
- BYSI 99.5M
- AVTX 90.9M
- IPO Year
- BYSI 2017
- AVTX 2015
- Fundamental
- Price
- BYSI $1.62
- AVTX $12.58
- Analyst Decision
- BYSI
- AVTX Buy
- Analyst Count
- BYSI 0
- AVTX 2
- Target Price
- BYSI N/A
- AVTX $35.00
- AVG Volume (30 Days)
- BYSI 25.5K
- AVTX 64.4K
- Earning Date
- BYSI 01-01-0001
- AVTX 11-07-2024
- Dividend Yield
- BYSI N/A
- AVTX N/A
- EPS Growth
- BYSI N/A
- AVTX N/A
- EPS
- BYSI N/A
- AVTX N/A
- Revenue
- BYSI $1,876,000.00
- AVTX $820,000.00
- Revenue This Year
- BYSI N/A
- AVTX N/A
- Revenue Next Year
- BYSI N/A
- AVTX N/A
- P/E Ratio
- BYSI N/A
- AVTX N/A
- Revenue Growth
- BYSI 21.03
- AVTX N/A
- 52 Week Low
- BYSI $0.78
- AVTX $3.95
- 52 Week High
- BYSI $4.00
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- BYSI 24.99
- AVTX 52.17
- Support Level
- BYSI $1.85
- AVTX $12.00
- Resistance Level
- BYSI $2.10
- AVTX $13.59
- Average True Range (ATR)
- BYSI 0.17
- AVTX 0.96
- MACD
- BYSI -0.05
- AVTX -0.15
- Stochastic Oscillator
- BYSI 15.02
- AVTX 33.52
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).